Description

The U.S. anticoagulant market is on the verge of a potential major shift in clinical practice, from a market dominated by a single injectable anticoagulant to a highly competitive market dominated by first-in-class novel oral anticoagulants. While these novel oral agents are expected to become standard of care for stroke prevention in atrial fibrillation patients, injectable agents will likely maintain their hold on certain hospital-based critical care applications. This research service covers the U.S. anticoagulant market from 2008 to 2016, with 2010 as the base year. Included are products on the market, products in development, and patient and revenue forecasts. Market challenges, drivers and restraints are identified and assessed.